Candel Therapeutics (NASDAQ:CADL) Upgraded at HC Wainwright

HC Wainwright upgraded shares of Candel Therapeutics (NASDAQ:CADL) to a buy rating in a research note issued to investors on Monday morning, MarketBeat Ratings reports. HC Wainwright currently has $23.00 price objective on the stock. HC Wainwright also issued estimates for Candel Therapeutics’ Q2 2025 earnings at ($0.15) EPS, Q3 2025 earnings at ($0.16) EPS, Q4 2025 earnings at ($0.17) EPS, FY2025 earnings at ($0.38) EPS, FY2026 earnings at ($0.44) EPS, FY2027 earnings at ($0.30) EPS, FY2028 earnings at $0.06 EPS and FY2029 earnings at $1.09 EPS.

Separately, Wall Street Zen raised Candel Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, May 22nd. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $22.00.

Candel Therapeutics Trading Up 2.9%

CADL opened at $4.99 on Monday. The firm has a market capitalization of $250.00 million, a price-to-earnings ratio of -3.72 and a beta of -0.91. The company’s 50 day simple moving average is $5.22 and its two-hundred day simple moving average is $6.73. Candel Therapeutics has a 1-year low of $3.79 and a 1-year high of $14.60. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.64 and a quick ratio of 4.64.

Candel Therapeutics (NASDAQ:CADL) last announced its quarterly earnings results on Tuesday, May 13th. The company reported $0.13 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.37. Analysts expect that Candel Therapeutics will post -1.47 EPS for the current fiscal year.

Hedge Funds Weigh In On Candel Therapeutics

A number of hedge funds have recently made changes to their positions in CADL. MetLife Investment Management LLC lifted its stake in shares of Candel Therapeutics by 9.7% during the fourth quarter. MetLife Investment Management LLC now owns 13,773 shares of the company’s stock worth $120,000 after purchasing an additional 1,215 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Candel Therapeutics by 12.4% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,165 shares of the company’s stock worth $106,000 after purchasing an additional 1,340 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in shares of Candel Therapeutics by 15.2% in the fourth quarter. JPMorgan Chase & Co. now owns 10,426 shares of the company’s stock worth $90,000 after acquiring an additional 1,375 shares in the last quarter. Russell Investments Group Ltd. grew its stake in Candel Therapeutics by 75.1% during the 4th quarter. Russell Investments Group Ltd. now owns 3,753 shares of the company’s stock valued at $33,000 after purchasing an additional 1,610 shares in the last quarter. Finally, Nuveen Asset Management LLC grew its stake in Candel Therapeutics by 3.0% during the 4th quarter. Nuveen Asset Management LLC now owns 68,226 shares of the company’s stock valued at $592,000 after purchasing an additional 2,009 shares in the last quarter. Institutional investors and hedge funds own 13.93% of the company’s stock.

Candel Therapeutics Company Profile

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.